Production (Stage)
Monopar Therapeutics Inc.
MNPR
$37.11
-$0.905-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.57M | -15.59M | -6.47M | -7.12M | -7.61M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.72M | 5.69M | 1.34M | 1.61M | 1.75M |
| Change in Net Operating Assets | -561.30K | 3.49M | -813.30K | -1.31M | -1.38M |
| Cash from Operations | -10.41M | -6.40M | -5.95M | -6.82M | -7.24M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.68M | -14.34M | 2.97M | 1.97M | 4.93M |
| Cash from Investing | -13.68M | -14.34M | 2.97M | 1.97M | 4.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.22M | 59.40M | 3.53M | 3.79M | 4.45M |
| Repurchase of Common Stock | -224.50K | -104.10K | -42.50K | -34.20K | -40.80K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 55.99M | 59.29M | 3.49M | 3.75M | 4.40M |
| Foreign Exchange rate Adjustments | 2.10K | 500.00 | -4.10K | -1.80K | -7.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.90M | 38.55M | 504.80K | -1.09M | 2.08M |